Historical reflections on autoimmune hepatitis

World Journal of Gastroenterology

Volumn 14, Issue 21, 2008, Pages 3292-3300

  Mackay, Ian R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Autoimmune hepatitis; HLA disease associations; Immunosuppressive therapy; Liver disease autoantibodies; Lupoid hepatitis; Medical history

Indexed keywords

ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CORTISONE; HEPATITIS B SURFACE ANTIGEN; HLA ANTIGEN; LIPOPROTEIN; LIVER KIDNEY MICROSOMAL ANTIGEN 1; MICROSOME ANTIBODY; PREDNISOLONE; SMOOTH MUSCLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CELL HETEROGENEITY; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HISTORY OF MEDICINE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FUNCTION; LONG TERM CARE; LUPOID HEPATITIS; POPULATION GENETICS; PREVALENCE; RACE DIFFERENCE; SEROLOGY; SURVIVAL;

EID: 54349115437     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3292     Document Type: Article

References (79)

1. Mackay IR. Chronic active hepatitides. Front Gastrointest Res 1975; 1: 142-187
2. Mackay IR, Tait BD. The history of autoimmune hepatitis. In: Autoimmune Hepatitis, Nishioka M, Toda G. Zeniya M Eds. Amsterdam: Elsevier, 1994: 3-23
3. Reuben A. A sheep in wolf's clothing. Hepatology 2003; 38: 1596-1601
4. Waldenstrom J, Leber, Blutproteine und Nahrungseiweiss. Dtsch Ges Verdau Stoffwechselkr 1950; 15: 113-119
5. Stern KG, Reiner M. Electrophoresis in medicine. Yale J Biol Med 1946; 19: 67-99
6. Himsworth HP. Lectures on the Liver and its Diseases. Oxford: Blackwell, 1947: 158-161
7. Zimmerman HJ, Heller P, Hill R P. Extreme hyperglobulinemia in subacute hepatic necrosis. N Engl J Med 1951; 244: 245-249
8. Neefe JM. Recent advances in the knowledge of 'virus hepatitis'. Med Clin N Amer 1946; 39: 1407-1443
9. Barker MH, Capps RB, Allen, FW. Chronic hepatitis in the Mediterranean theatre. JAMA 1945; 129: 653-659
10. Capps RB. Clinical aspects of the sequelae of acute hepatitis. Gastroenterology 1948; 11: 680-690
11. Wood IJ, King WE, Parsons PJ, Perry JW, Freeman M, Lim-Brick L. Non-suppurative hepatitis: a study of acute and chronic forms with special reference to biochemical and histological changes. Med J Austr 1948; 1: 249-261
12. Kunkel HG, Labby DH. Chronic liver disease following infectious hepatitis. II. Cirrhosis of the liver. Ann Intern Med 1950; 32: 433-450
13. Leibowitz S. Virus hepatitis implications of its chronic stages. J Insur Med 1950; 5: 10-18
14. Kunkel HG, Ahrens EH, Eisenmenger WJ, Bongiovanni AM, Slater RJ. Extreme hypergammaglobulinemia in young women with liver disease. J Clin Invest 1951; 30: 654
15. Saint EG, King WE, Joske RA, Finckh ES. The course of infectious hepatitis with special reference to prognosis and the chronic stage. Australas Ann Med 1953; 2: 113-127
16. Joske RA, King WE. The L.E.-cell phenomenon in active chronic viral hepatitis. Lancet 1955; 269: 477-480
17. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the "tart" cell and the "L.E." cell. Proc Staff Meet Mayo Clin 1948; 23: 25-28
18. Hargraves MM. Discovery of the LE cell and its morphology. Mayo Clin Proc 1969; 44: 579-599
19. Haserick JR, Lewis LA, Bortz DW. Blood factor in acute disseminated lupus erythematosus; determination of gamma globulin as specific plasma fraction. Am J Med Sci 1950; 219: 660-663
20. Mackay IR, Gajdusek DC. An autoimmune reaction against human tissue antigens in certain acute and chronic diseases. II. Clinical correlations. AMA Arch Intern Med 1958; 101: 30-46
21. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis. Lancet 1956; 271: 1323-1326
22. Bearn AG, Kunkel HG, Slater RJ. The problem of chronic liver disease in young women. Am J Med 1956; 21: 3-15
23. Reynolds TB, Edmondson HA, Peters RL, Redeker A. Lupoid hepatitis. Ann Intern Med 1964; 61: 650-666
24. Mackay IR Hepatic disease and systemic lupus erythematosus: coincidence or convergence. In: Lahita RG, editor. Systemic Lupus Erythematosus. 4ed. San Diego: Elsevier, 2004: 993-1017
25. Mackay IR. The problem of persisting destructive disease of the liver. Gastroenterology 1961; 40: 617-626
26. Holborow EJ, Asherson GL, Johnson GD, Barnes RD, Carmichael DS. Antinuclear factor and other antibodies in blood and liver diseases. Br Med J 1963; 1: 656-658
27. Mackay IR, Weiden S, Hasker J. Autoimmune hepatitis. Ann N Y Acad Sci 1965; 124: 767-780
28. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005
29. Soloway RD, Summerskill WH, Baggenstoss AH, Schoenfield LJ. "Lupoid" hepatitis, a nonentity in the spectrum of chronic active liver disease. Gastroenterology 1972; 63: 458-465
30. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet 1959; 1: 65-69
31. Last PM. The treatment of active chronic infectious hepatitis with ACTH (corticotrophin) and cortisone. Med J Aust 1957; 44: 672-676
32. O'Brien EN, Goble AJ, Mackay IR. Plasma-transaminase activity as an index of the effectiveness of cortisone in chronic hepatitis. Lancet 1958; 1: 1245-1249
33. Mackay IR, Weiden S, Ungar B. Treatment of active chronic hepatitis and lupoid hepatitis with 6-mercaptopurine and azothioprine. Lancet 1964; 1: 899-902
34. Mackay IR. Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone. Q J Med 1968; 37: 379-392
35. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185
36. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-627
37. Klatskin G. Subacute hepatic necrosis and postnecrotic cirrhosis due to anicteric infections with the hepatitis virus. Am J Med 1958; 25: 333-358
38. Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol 1971; 105: 13-20
39. Searle J, Harmon BV, Bishop CJ, and Kerr JFR. Significance of single cell death by apoptosis in hepatobiliary disease. J Gastroenterol Hepatol 1987; 2: 77-96
40. Popper H, Paronetto F, Schaffner F. Immune processes in the pathogenesis of liver disease. Ann N Y Acad Sci 1965; 124: 781-799
41. Dienes HP. Viral and autoimmune hepatitis. Stuttgart: Fischer Verlag, 1989: 47-51
42. Page AR, Good RA. Plasma-cell hepatitis, with special attention to steroid therapy. AMA J Dis Child 1960; 99: 288-314
43. De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uehlinger E. A classification of chronic hepatitis. Lancet 1968; 2: 626-628
44. Acute and chronic hepatitis revisited. Review by an international group. Lancet 1977; 2: 914-919
45. Whittingham S, Mackay IR, Thanabalasundrum RS, Chuttani HK, Manjuran R, Seah CS, Yu M, Viranuvatti V. Chronic liver disease: differences in autoimmune serological reactions between Australians and Asians. Br Med J 1973; 4: 517-519
46. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann intern Med 1967; 66: 924-931
47. Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc. Natl Acad Sci USA 1968; 60: 814-821
48. Mackay IR. The prognoses of chronic hepatitis. Ann Intern Med 1972; 77: 649-651
49. Pedersen JS, Toh BH, Mackay IR, Tait BD, Gust ID, Kastelan A, Hadzic N. Segregation of antoantibody to cytoskeletal filaments, actin and intermediate filaments with two types of chronic active hepatitis. Clin Exp Immunol 1982; 48: 527-532
50. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Beschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
51. Mackay IR, Morris PJ. Association of autoimmune active chronic hepatitis with HL-A1,8. Lancet 1972; 2: 793-795
52. Mackay IR, Tait BD. HLA associations with autoimmune type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980; 79: 95-98
53. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autommume hepatitis. Immunol Rev 2000; 174; 250-259
54. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13; 701-706
55. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autommume hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004, 1: 2
56. Mackay IR. Chronic hepatitis. In; Rose NR, Mackay IR, editors. The Autoimmune Diseases. 4th ed. San Diego: Academic Press, 2006: 729-747
57. Vergani D, Alvarez F, Bianchi FB, Canvcado EL, Mackay IR, Manns MP, Nishioka M. Penner E. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683
58. Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 1965; 2: 878-879
59. Whittingham S, Irwin J, Mackay IR, Smalley M. Smooth muscle autoantibody in "autoimmune" hepatitis. Gastroenterology 1966; 51: 499-505
60. Whittingham S, Mackay IR, Irwin J. Autoimmune hepatitis. Immunofluorescence reactions with cytoplasm of smooth muscle and renal glomerular cells. Lancet 1966; 1: 1333-1335
61. Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 1976; 29: 403-410
62. Gabbiani G, Ryan GB, Lamelin JP, Vassalli P, Majno G, Bouvier CA, Cruchaud A, Lescher EF. Human smooth muscle autoantibody. Its identification as antiactin antibody and a study of its binding to "nonmuscular" cells. Am J Pathol 1973; 72: 473-488
63. Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 1979; 38: 621-628
64. Mackay IR, Martinez-Neira R, Whittingham S, Nicolau D, Toh B-H. Autoantigenicity of Actin in: dos Remedios C, Chhabra D Eds, Actin, Actin-binding Proteins and Disease. New York: Springer, 2008: 50-64
65. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973; 15: 331-344
66. Alvarez F, Bernard O, Homberg JC, Kreibich G. Anti-liverkidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum. J Exp Med 1985; 161: 1231-1236
67. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy VG, Grippon P. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-1339
68. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 1066-1072
69. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-882
70. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39: 1066-1074
71. Berg PA, Stechemesser E, Strienz J. Hypergammaglob ulinämische chronisch aktive Hepatitis mit Nachweis von leber-pankreas-spezifischen komplemtbindenden Autoantiköpern. Verh Dtsch Ges Inn Med 1981; 87: 921-927
72. Manns M, Gerken G, Kyriatsoulis A, Staritz M, and Meyer zum Büschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-294
73. Meyer zum Buschenfelde KH, Hutteroth TH, Manns M, Moller B. The role of liver membrane antigens as targets in autoimmune type liver disease. Springer Semin Immunopathol 1980; 3: 297-315
74. Chisari FV. Liver-specific protein in perspective. Gastroenterology 1980; 78: 168-170
75. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984; 55: 347-354
76. Treichel U, McFarlane BM, Seki T, Krawitt EL, Alessi N, Stickel F, McFarlane IG, Kiyosawa K, Furuta S, Freni MA. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107: 799-804
77. Swanson NR, Reed WD, Yarred LJ, Shilkin KB, Joske RA. Autoantibodies to isolated human hepatocyte plasma membranes in chronic active hepatitis. II. Specificity of antibodies. Hepatology 1990; 11: 613-621
78. Matsuo I, Ikuno N, Omagari K, Kinoshita H, Oka M, Yamaguchi H, Kohno S, Mackay IR. Autoimmune reactivity of sera to hepatocyte plasma membrane in type 1 autoimmune hepatitis. J Gastroenterol 2000; 35: 226-234
79. Mackay IR, Toh BH. Autoimmune hepatitis: the way we were, the way we are today and the way we hope to be. Autoimmunity 2002; 35: 293-305